AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 10, 2026, 8:00 AM ET Corbus Pharmaceuticals reported a Q3 2026 net loss of approximately $37.8 million and $115.3 million in cash, expected to fund operations into 2028. AI-generated summary · Source: company release
Nasdaq: $CRBPOncology and obesityNectin-4 ADCPeripheral CB1

CRBP Stock Hub: Corbus Pharmaceuticals News, CRB-701 and CRB-913

TEMPO-1 and CANYON-1 test different clinical propositions. The registrational oncology study requires controlled benefit, while early obesity weight loss needs longer safety and persistence evidence. Cash, equivalents and investments were $115.3 million at September 30, 2026. The November 10 regular-session close was $3.93 (+11.65% versus $3.52 on November 9).

Last updated: November 10, 2026Market reference: November 10, 2026 regular-session closeFinancial period: September 30, 2026 (third-quarter release)Archive research: October 23, 2026
Full research report · PDF
Corbus Pharmaceuticals ($CRBP), research updated November 10, 2026
16 pages covering the business, third-quarter 2026 results and the $15.0 million CSPC milestone, the September 30 cash position and the company’s forecast of funding into 2028, at-the-market sales and the November 6 share count, Nectin-4 ADC evidence and ocular toxicity, TEMPO-1, peripheral CB1 obesity data and psychiatric tolerability, licensing, scenarios, sources and FAQ. For personal use only: redistribution prohibited.
Get the report (PDF)
Next announced scientific presentation
November 15, 2026 · CANYON-1 at ObesityWeek

The scheduled poster covers CRB-913 efficacy, safety and tolerability. Additional detail is separate from a new pivotal result or approval. Company announcement

Investor conferences: CEO Yuval Cohen presented at the Guggenheim 3rd Annual Healthcare Innovation Conference on November 9 (8:00 a.m. ET); fireside chats follow at the Jefferies Global Healthcare Conference on November 18 (9:00 a.m. GMT) and the Evercore Healthcare Conference on December 1 (10:25 a.m. ET). Conference schedule. First-line oncology combination data are targeted for Q1 2027 and CANYON-2 initiation for H1 2027. TEMPO-1’s larger controlled evidence is targeted for 2028; these remain company windows.
Corbus Pharmaceuticals CRBP daily stock chart
Daily chart $CRBP. The chart link is an affiliate link. Interactive chart with bull and bear scenarios on JC Just Charts →

CRBP stock at a glance

Close · November 10, 2026
$3.93
Regular session; +11.65% versus $3.52 on November 9.
Cash + investments · Sep. 30
$115.3M
Reported November 10; $117.941M at June 30. Historical balance, not current cash. Source
Q3 2026 net loss
$37.8M
Includes a $15.0M CSPC development milestone; $23.3M a year earlier. Nine-month operating cash use was $76.4M. Source · 10-Q
ATM capacity · September 30
~$115.2M
Available under the Jefferies at-the-market agreement at September 30, per the Form 10-Q (the August 7 prospectus set $127.5M before later sales); Q3 sales totalled 1,932,621 shares for ~$18.6M net. Capacity, not cash. Source
CANYON-1 placebo-adjusted loss
5.0%
12-week LS mean; assigned 60 mg group.
CANYON-1 randomized
254 adults
Without diabetes; early-duration trial, not chronic validation.
TEMPO-1 first dosing
September 29
Achieved milestone; randomized benefit remains ahead.
Company funding guidance
Into 2028
Operating-plan estimate restated November 10, 2026, conditional on spending and financing.

Where Corbus Pharmaceuticals stands now

CRB-701 is a Nectin-4/MMAE antibody-drug conjugate being tested in previously treated oropharyngeal cancer. CRB-913 is an oral peripheral CB1 inverse agonist for obesity. The programs differ in evidence, tolerability and development needs. A Schedule 13G/A filed October 29 reports zero beneficial ownership for Aberdeen Group and abrdn Inc. for a September 16 event; the filing date is not a new same-day sale. SEC ownership amendment

On November 10, 2026 Corbus reported third-quarter results: a net loss of about $37.8 million ($1.81 per share), against $23.3 million a year earlier, and operating expenses of about $38.8 million, up $14.4 million mainly because of a $15.0 million development milestone incurred under the CSPC licence for sutantatug envedotin (CRB-701). Cash, cash equivalents and investments were $115.3 million at September 30, which the company expects to fund operations into 2028 under current plans. Corbus also restated that first-line combination data with Keytruda in oropharyngeal cancer are expected in Q1 2027, that the CANYON-1 late-breaking poster is scheduled at ObesityWeek on November 15, and that it plans to engage with the FDA on the CRB-913 development plan while evaluating a combination with GLP-1 therapy. Q3 2026 release

The Form 10-Q filed the same day adds that Corbus sold 1,932,621 shares through its at-the-market program with Jefferies in the third quarter, for net proceeds of about $18.6 million (2,826,665 shares and $27.6 million over nine months); about $115.2 million remained available under the agreement at September 30. Nine-month operating cash use was $76.4 million, and 20,606,760 common shares were outstanding on November 6; 1,025,000 pre-funded warrants remained outstanding at September 30. In the filing the company expects its cash, equivalents and investments to meet operating and capital requirements for at least twelve months from the report’s issuance. Form 10-Q

Tumor responses and short-duration weight loss need controlled and durable confirmation. CRB-701’s ocular toxicity, interruptions and small evaluable cohorts constrain early response interpretation. Psychiatric discontinuations and gastrointestinal effects matter to CRB-913 persistence. Licensed territories, milestones, royalties, cash use and potential share issuance affect retained economics.

The constructive case

Indication-specific oncology activity and a differentiated oral obesity mechanism provide separate opportunities if controlled benefit, longer tolerability and financing support development.

The cautious case

Clinical signals can weaken with broader enrollment or longer exposure. Ocular burden, psychiatric tolerability, trial spending and dilution can reduce the per-share outcome before either asset generates revenue.

Latest Corbus Pharmaceuticals news

Nov 10, 2026

Corbus Pharmaceuticals reports Q3 2026 financial results and provides a corporate update

Corbus Pharmaceuticals reported a net loss of approximately $37.8 million, or $1.81 per basic and diluted share, for the quarter ended September 30, 2026. Operating expenses increased to approximately $38.8 million, primarily due to a $15.0 million development milestone under the CSPC licensing agreement. The company had $115.3 million of cash, cash equivalents, and investments, expected to fund operations into 2028. The update also covered dosing in the TEMPO-1 study of sutantatug envedotin and topline CANYON-1 data for CRB-913.

Nov 5, 2026

Corbus Pharmaceuticals to participate in upcoming investor conferences in November

Corbus Pharmaceuticals announced that CEO Yuval Cohen, Ph.D., will present a corporate overview and meet investors at three conferences. The Guggenheim 3rd Annual Healthcare Innovation Conference presentation is on Monday, November 9, 2026. The Jefferies Global Healthcare Conference fireside chat is on Wednesday, November 18, 2026, and the 9th Annual Evercore Healthcare Conference fireside chat is on Tuesday, December 1, 2026.

Oct 29, 2026

Ownership amendment reports zero beneficial holdings

Aberdeen Group and abrdn Inc. report zero shares and 0% for an event dated September 16. The statement was signed October 5 and filed October 29. It does not establish an October 29 sale or aggregate institutional ownership.

Oct 22, 2026

CANYON-1 poster scheduled for November 15

The late-breaking ObesityWeek poster will address CRB-913 efficacy, safety and tolerability. The presentation can add detail without itself establishing long-term obesity benefit.

Sep 29, 2026

First patient dosed in TEMPO-1

The randomized registrational OPSCC study compares CRB-701 with investigator-selected monotherapy. Response and survival address different potential regulatory stages.

Sep 14, 2026

CANYON-1 reports early weight-loss signal

The trial randomized 254 adults without diabetes. The assigned 60 mg group had 5.0% placebo-adjusted LS mean weight loss at 12 weeks, alongside psychiatric and other tolerability questions for longer exposure.

CRBP stock catalysts: CANYON-1 detail and controlled oncology evidence

  • November 9, 2026 · 8:00 a.m. ET — Guggenheim 3rd Annual Healthcare Innovation Conference: corporate presentation by CEO Yuval Cohen and one-on-one investor meetings. Held
  • November 10, 2026 — Third-quarter 2026 results: $115.3 million of cash and investments at September 30, net loss of about $37.8 million including a $15.0 million CSPC milestone; funding expected into 2028. Form 10-Q filed the same day. Reported
  • November 15, 2026 — ObesityWeek CANYON-1 scientific poster. Company-announced presentation
  • November 18, 2026 · 9:00 a.m. GMT — Jefferies Global Healthcare Conference: fireside chat and one-on-one investor meetings. Company-announced schedule
  • December 1, 2026 · 10:25 a.m. ET — 9th Annual Evercore Healthcare Conference: fireside chat and one-on-one investor meetings. Company-announced schedule
  • Q1 2027 — First-line CRB-701 combination data targeted. Company clinical window
  • H1 2027 — Planned CANYON-2 Phase 2 initiation. Company execution target
  • 2028 — Larger controlled TEMPO-1 evidence targeted. Company window, not promised outcome

Scientific presentation · TEMPO-1 · Obesity development · Investor conferences

CRBP CRB-701: indication-specific responses and ocular toxicity

OPSCC and other head-and-neck cancers should not be pooled into an undifferentiated response claim. Evaluable-patient percentages exclude some participants lacking scans. Ocular events, dose interruptions and reductions affect exposure and treatment burden; response alone is not evidence of survival benefit.

CRBP CRB-913: chronic persistence, funding and licensed economics

A 12-week weight-loss signal is an early test of a chronic medicine. Psychiatric tolerability and treatment persistence require longer study. The two development programs share corporate funding while carrying different milestone and royalty obligations. ATM capacity and potential warrant proceeds are distinct from cash already held.

Merlintrader Health Score · $CRBP

3.00out of 5
Balance sheet and runway · 30%3.0

$115.3 million of cash and investments at September 30, 2026 and company guidance into 2028, restated on November 10, support development; the third quarter included a $15.0 million CSPC milestone, nine-month operating cash use was $76.4 million, and oncology and obesity costs can rise.

Catalysts · 30%3.5

A dated scientific presentation and Q1/H1 2027 windows provide milestones while larger controlled oncology evidence remains later.

Dilution · 20%2.0

Common shares were 20,606,760 on November 6 (19,341,293 on August 4); third-quarter ATM sales totalled 1,932,621 shares for about $18.6 million net, and about $115.2 million of ATM capacity remained at September 30, alongside 1,025,000 pre-funded warrants and employee awards.

Trading liquidity · 10%3.0

On November 10 the shares closed at $3.93 (+11.65%) on 643,006 shares traded, against a three-month average of about 1.06 million shares a day; clinical events can create gaps.

Execution · 10%3.5

CANYON-1 completion and TEMPO-1 first dosing are achieved; chronic safety and randomized confirmation remain ahead.

Assessed October 22, 2026; reassessed November 10, 2026, after the third-quarter results and the Form 10-Q filed that day (ATM sales, nine-month cash use, November 10 trading data), with the scores unchanged. Weighted calculation: 3.0×30% + 3.5×30% + 2.0×20% + 3.0×10% + 3.5×10% = 3.00. This describes financial and operational robustness over twelve to eighteen months, not an investment recommendation.

Red flags

  • CRB-701 ocular toxicity and evaluable denominators constrain early efficacy comparisons.
  • CRB-913 psychiatric tolerability matters to longer treatment and persistence.
  • Company clinical windows are not confirmed regulatory outcomes.
  • Financing capacity, contingent proceeds and licensing costs differ from current resources.
  • The ATM program was used in the third quarter (1,932,621 shares, about $18.6 million net); further sales from the about $115.2 million available at September 30 would add shares.

CRBP Stock FAQ: Corbus Pharmaceuticals Questions Answered

What is the next CRBP stock catalyst?

Corbus scheduled its CANYON-1 CRB-913 poster for November 15, 2026, from 2:30 to 3:30 p.m. ET at ObesityWeek, according to its October 22 announcement. Later guidance targets first-line CRB-701 combination data in Q1 2027 and initiation of the next CRB-913 Phase 2 monotherapy study in the first half of 2027. ObesityWeek presentation schedule. Oncology combination-data guidance. Next obesity-study guidance.

Are Corbus’s CRB-701 and CRB-913 FDA approved?

Corbus’s CRB-701 and CRB-913 remained investigational in its October 22, 2026 pipeline update. CRB-701 is an oncology antibody-drug conjugate; CRB-913 is an oral obesity candidate. FDA clearance to start the CRB-701 TEMPO-1 study permits clinical testing, while Fast Track designation supports development; neither is marketing approval. Investigational pipeline. TEMPO-1 initiation and regulatory status.

How much cash does Corbus Pharmaceuticals have, and how long will it last?

Corbus reported $115.3 million in cash, cash equivalents and investments at September 30, 2026, and on November 10 said it expects that to fund operations into 2028 based on current operating plans. At June 30 the total was $117.9 million: cash and equivalents of $23.370 million and investments of $94.571 million. The third-quarter net loss was about $37.8 million, including a $15.0 million CSPC milestone, and operating cash use was $76.4 million for the first nine months ($55.197 million in the first half), according to the Form 10-Q; future development spending can change the funding outlook. Q3 2026 resources and funding guidance. Q3 Form 10-Q. June resources (Q2 release). Balance sheet and cash-flow statement.

Is CRBP stock at risk of further dilution?

Corbus’s August 7, 2026 prospectus permits up to $127.5 million of common-stock sales through its ATM program. That is potential issuance capacity, not cash already raised. In the third quarter Corbus sold 1,932,621 shares under the program for about $18.6 million net; about $115.2 million remained available under the agreement at September 30. It had 20,606,760 common shares outstanding on November 6 (19,341,293 on August 4), and 1,025,000 pre-funded warrants were outstanding at September 30; warrants, equity awards and further financing can add shares and dilute existing holders. August ATM prospectus. Dated share capital and potential dilution. Q3 ATM sales and November 6 share count.

When does Corbus Pharmaceuticals report earnings?

Corbus reported third-quarter 2026 results on November 10, 2026, covering the quarter ended September 30; as of that date it had not announced the date of its next results release. Q3 2026 results. The upcoming November 15 ObesityWeek presentation concerns CRB-913 clinical data, rather than a scheduled earnings release. Company announcements. Upcoming company events. August 6 second-quarter release.

What does Corbus Pharmaceuticals do?

As of October 22, 2026, Corbus is a clinical-stage biotechnology company focused on cancer and obesity treatments. CRB-701 targets Nectin-4-expressing tumors with an antibody-drug conjugate and is in the TEMPO-1 registrational study. CRB-913 is an oral, peripherally restricted CB1 inverse agonist in development for obesity. They are different drug programs. Company and pipeline. Oncology study status.

How much weight loss did Corbus’s CRB-913 show in CANYON-1?

Corbus’s September 14, 2026 topline release reported 5.0% placebo-adjusted least-squares mean weight loss at Week 12 in the group assigned CRB-913 60 mg. The Phase 1b study evaluated short-term treatment with dose titration. It is not evidence of long-term efficacy or tolerability; comparisons with other drugs were across trials, rather than randomized head-to-head comparisons. CANYON-1 population, estimand and results.

Did Aberdeen sell its Corbus shares on October 29, 2026?

The Corbus ownership filing submitted October 29, 2026 reports zero beneficial ownership for Aberdeen Group and abrdn Inc. with a September 16, 2026 event date. It was signed October 5. The disclosure is therefore not evidence of a sale on the filing date, and does not identify the exact dates and prices of the underlying disposals. Ownership declaration, event date and signature. Filing date and accession metadata.

Primary sources

Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $CRBP or any other security.

Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.

Biotechnology companies face clinical, safety, regulatory, manufacturing, commercial and financing risks. Trials can fail, adverse effects can limit use, regulatory applications can be delayed or rejected, and an approved medicine may not achieve commercial expectations. Additional borrowing or equity issuance can increase obligations or dilute existing shareholders. Investors can lose part or all of their capital. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.

Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.